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Abstract 
The α subunit of the cardiac voltage-gated sodium channel, NaV1.5, provides the rapid 
sodium inward current that initiates cardiomyocyte action potentials. Here, we analyzed 
for the first time the post-translational modifications of NaV1.5 purified from end-stage 
heart failure human cardiac tissue. We identified R526 methylation as the major post-
translational modification of any NaV1.5 arginine or lysine residue. Unexpectedly, we 
found that the N terminus of NaV1.5 was: 1) devoid of the initiation methionine, and 2) 
acetylated at the resulting initial alanine residue. This is the first evidence for N-terminal 
acetylation in any member of the voltage-gated ion channel superfamily. Our results 
open the door to explore NaV1.5 N-terminal acetylation and arginine methylation levels 
as drivers or markers of end-stage heart failure. 
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1. Introduction 
 
The cardiac voltage-gated sodium channel is responsible for the sodium inward 
current that initiates cardiomyocyte action potentials. The pore-forming α-subunit of the 
cardiac sodium channel (NaV1.5) forms the core of the sodium channel [1]. NaV1.5 is a 
large integral membrane protein that spans more than 2,000 residues, and includes 24 
transmembrane segments. NaV1.5 is predicted to be organized in four homologous 
domains, DI to DIV, joined by interdomain linkers. The N and C termini of the protein, 
as well as interdomain linkers, are cytosolic and accessible to post-translational 
modifications (PTMs).  
Genetic mutations in NaV1.5 increase the risk of sudden cardiac death due to 
e.g. Brugada syndrome [2]. Additionally, NaV1.5 current has been shown to be altered 
in acquired diseases; for instance, due to reduction of NaV1.5 protein expression in the 
setting of heart failure (HF) [3]. Mechanisms include the expression of non-functional 
NaV1.5 splicing variants that may increase NaV1.5 degradation [4, 5]. PTMs may also 
underlie the decrease in NaV1.5 current documented in HF. For example, NaV1.5 
phosphorylation by Ca2+/CaM-dependent protein kinase II (CaMKII), is thought to 
contribute to NaV1.5 loss-of-function in HF [6].  
The linker between domains DI and DII of NaV1.5 is the hot-spot of PTMs, 
including phosphorylation and arginine methylation [7, 8]. Arginine methylation is 
emerging as an important novel PTM of voltage-gated ion channels. First, we detected 
methylation of R513, R526 and R680 in NaV1.5 expressed in HEK293 cells [8], and 
showed that arginine methylation regulates NaV1.5 plasma membrane expression [9]. 
The fact that R513H, R526H and R680H are NaV1.5 mutations associated to sudden 
cardiac death syndromes suggests that NaV1.5 arginine methylation is relevant to 
cardiac disease. In the same line, Baek et al have observed that levels of arginine 
methylation (including R513 methylation, NaV1.5 numbering) of the brain voltage-gated 
sodium channel, NaV1.2, increase after induction of seizure in rats [10].  
Given the growing evidence that indicates that NaV1.5 PTMs play a role in 
cardiac disease, the lack of proteomic studies of NaV1.5 purified from human cardiac 
tissue, and the clinical relevance of NaV1.5 current alterations in HF, we set ourselves 
to elucidate the PTMs of NaV1.5 purified from end-stage HF human cardiac tissue. We 
identified R526 methylation as the major PTM of NaV1.5 basic residues, and we found 
that the N terminus of NaV1.5 was devoid of the initiation methionine, and acetylated at 
the resulting initial alanine residue. These results may provide a novel mechanism for 
the reduced NaV1.5 current in end-stage HF. 
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2. Materials and Methods 
 
2.1 NaV1.5 purification  
 
Human heart tissue samples were obtained from myocardial biopsies of four end-stage 
HF patients undergoing heart transplantation. Two patients had been diagnosed with 
idiopathic dilated cardiomyopathy, and two with ischemic cardiomyopathy. With the 
written consent of the patients, left and right ventricle samples were collected from the 
explanted heart, and frozen immediately in liquid N2. Samples from the four patients 
were pooled, and the total amount of collected cardiac tissue was 126 g. All procedures 
were approved by the ethical committees of the Hospital Universitari de Girona Dr. 
Josep Trueta and the Hospital Universitari Clínic de Barcelona. 
 NaV1.5 protein enrichment was performed by immunopurification from integral 
membrane protein preparations using NaV1.5-specific antibodies (SC-271255, Santa 
Cruz Biotechnology). After SDS-PAGE separation, the putative NaV1.5 band was 
excised from the gel, and digested. To maximize sequence coverage, we performed 
two independent digestions using either trypsin, or chymotrypsin. See Supplementary 
Material for detailed Methods. 
 
 
2.2. Mass spectrometry 
 
Previously digested samples were analyzed by liquid chromatography coupled to mass 
spectrometry. Briefly, peptide digests were chromatographically separated using a 
reverse phase C18 column, and eluting peptides were analyzed on-line with a LTQ-
Orbitrap Velos Pro (Thermo) fitted with a nanospray source. Fragment ion spectra were 
produced either via collision induced dissociation (CID) and followed by acquisition in 
the ion trap mass analyzer, or by higher energy collisional dissociation (HCD) and 
acquired in the Orbitrap mass analyzer. For each survey scan, the twenty (CID) or ten 
(HCD) most intense ions were selected for fragmentation. All data were acquired with 
Xcalibur 2.1 software. 
Protein identification was performed with Proteome Discoverer (v.1.4.0.288) using 
either Sequest-HT or Mascot (v2.4) search engines, against the reference Uniprot 
human FASTA database (version 2014_06, 88949 entries), allowing for 3 missed 
cleavages, and using 7 ppm for the MS peptide mass tolerance and 0.5 Da (CID) or 20 
mmu (HCD) for the peptide mass tolerance for MS/MS spectra. Carbamidomethylation 
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of cysteines was set as static modification, and oxidation of methionine was set as 
variable modification. The following post-translational modifications were also added as 
variable modifications and searched for individually: mono- and dimethylation of 
arginine, mono-, di-, and trimethylation of lysine, lysine acetylation, palmitoylation, 
carbamylation, and formylation, protein N terminus acetylation. False discovery rates 
were set at 0.01 or 0.05 for high or medium confidence peptides, respectively. See 
Supplementary Material for detailed Methods. 
 
3. Results and Discussion 
 
Mass spectrometry analysis of NaV1.5 purified from the human heart has not previously 
been reported. Here, we report the analysis of PTMs of NaV1.5 purified from end-stage 
HF human cardiac tissue. 
 
3.1. NaV1.5 purification and mass spectrometric analysis 
 
Initially, left and right ventricle samples were collected from myocardial biopsies of end-
stage HF patients undergoing heart transplantation. Immunopurified NaV1.5 
(Supplementary Figure S1) from the explanted hearts was analyzed by mass 
spectrometry after trypsin or chymotrypsin-digestion, using either CID or HCD 
fragmentation. A total of 41 unique NaV1.5 peptides were identified (Supplementary 
Tables 1 and 2). NaV1.5 total coverage was ca. 26 % (Supplementary Figure S2), 
which was comparable to the 25 % sequence coverage reported by Marionneau et al 
after proteomic analysis of NaV1.5 purified from mouse cardiac tissue [7]. Coverage of 
the linker between domains DI and DII (59 %) was improved compared to that obtained 
after NaV1.5 FLAG-affinity purification from overexpressing HEK293 cells (40 %, [8]).  
 
3.2. NaV1.5 is N-terminally acetylated in end-stage HF 
 
We searched our proteomic data to explore the existence of NaV1.5 acetylation. Lysine 
acetylation was not observed. However, we found that the N terminus of NaV1.5, which 
was devoid of the initiation methionine, was acetylated at the N-terminal Ala2 (Figure 1, 
Supplementary Figure S3 and Supplementary Tables 2 and 3). This is the first 
evidence for N-terminal acetylation in any member of the voltage-gated ion channel 
superfamily, which consists of more than 140 proteins including calcium, potassium 
and sodium channels. 
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N-terminal acetylation is catalyzed by N-terminal acetyltransferases, which 
transfer acetyl groups from acetyl-coenzyme A to the α-amino group of the N-terminal 
residue, either Met or the resulting initial residue after Met excision by  
aminopeptidases [11]. In general, protein N-terminal acetylation triggers protein 
degradation by the ubiquitin-dependent proteasome [12]. This is consistent with the 
demonstrated role of the ubiquitin ligase Nedd4-2 in NaV1.5 internalization from cellular 
membranes [13]. The primary Nedd4-2 recognition site is the PY motif in NaV1.5 C 
terminus. Nevertheless, a recent report has shown that NaV1.5 lacking the N terminus 
domain was not targeted by the ubiquitin-dependent proteasome [14], supporting a role 
of the N-terminal domain in NaV1.5 ubiquitin-dependent degradation. 
Reduced NaV1.5 expression is typical of HF [3, 6]. In our samples, N-terminally 
acetylated NaV1.5 seemed to be the most abundant NaV1.5 form, because the 
corresponding unmodified peptide was not detected (Supplementary Table 1). It is 
tempting to speculate that N-terminal processing of NaV1.5 may be increased in end-
stage HF. This may reflect a higher NaV1.5 degradation rate during HF, perhaps as a 
cellular response to the expression of splicing variants, non-functional NaV1.5 channels 
[4]. This hypothesis is supported by the observation that the N terminus of NaV1.5 in 
hearts of healthy mice is intact (including the initiation methionine) [7]. Likewise, NaV1.5 
expressed in HEK293 cells includes Met1, and is not modified by acetylation [8], and 
NaV1.2 purified from rat brain is not N-terminally acetylated [10]. Further testing of this 
idea would greatly benefit from the generation of antibodies specifically targeting 
NaV1.5 N-terminal acetylation. 
 
Figure 1. NaV1.5 Ala2 is N-terminal acetylated. A. NaV1.5 topology highlighting 
acetylation of Ala2. B. Mass spectrum of acetylated NaV1.5 N-terminal tryptic peptide, 
using CID fragmentation. C. Mass spectrum of acetylated NaV1.5 N-terminal tryptic 
peptide, using HCD fragmentation. For each peptide, identified b (red) and y (blue) 
series ions are shown. Not detected ions are in black. 
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3.3. NaV1.5 is arginine methylated in end-stage HF 
 
Analysis of NaV1.5 post-translational methylation identified mono- and dimethylation of 
R526 with medium and high confidence, respectively (Figure 2, Supplementary Figure 
S3, and Supplementary Tables 2 and 4). Peptides containing unmodified R526 were 
not detected, probably due to an enhanced trypsin performance in the absence of a 
methyl group at R526, which leads to a SSR peptide too small for detection by our LC-
MS set up. Intriguingly, peptides containing unmodified R513 and R680 were observed, 
but not their methylated counterparts. Lysine methylation was not detected in any 
peptide.  
We then performed a comprehensive search for Arg and Lys PTMs. First, we 
searched for palmitoylation, carbamylation or formylation of lysine, but we did not 
detect these PTMs. Then, we conducted error-tolerant searches to identify edited 
residues. We observed known NaV1.5 PTMs and polymorphisms (Supplementary 
Table 5), but no new PTM was found.  
Overall, our results suggest that R526 methylation could be the predominant 
form of NaV1.5 Arg or Lys modification in end-stage HF. The fact that R526H is a 
known NaV1.5 mutation associated with Brugada syndrome [15], suggests that R526 
methylation levels are important for proper NaV1.5 function. Further investigations 
should assess whether arginine methylation patterns differ in control and HF samples. 
In particular, it will be interesting to search for R513 and R680 methylation in control 
cardiac tissue. 
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Figure 2. NaV1.5 R526 is mono- and dimethylated. A. NaV1.5 topology highlighting 
mono- and dimethylation of R526. B. Mass spectrum of tryptic NaV1.5 peptide 
containing monomethylated R526, using CID fragmentation. C. Mass spectrum of 
tryptic NaV1.5 peptide containing dimethylated R526, using CID fragmentation. D. Mass 
spectrum of tryptic NaV1.5 peptide containing dimethylated R526, using HCD 
fragmentation. We could not infer the methylation pattern (symmetric or asymmetric) of 
dimethylated R526 from the corresponding spectra. For each peptide, identified b (red) 
and y (blue) series ions are shown. Not detected ions are in black. 
 
 
 
3.4 Conclusions 
 
In this study we performed a characterization of PTMs of NaV1.5 purified from end-
stage HF human heart tissue. Our study led to 1) the discovery of N-terminal 
acetylation as a novel modification of voltage-gated ion channels; 2) the detection of 
NaV1.5 N-terminal acetylation in end-stage HF; and 3) the identification of R526 
methylation as the major NaV1.5 methylation site in end-stage HF. Future studies 
should be addressed at investigating these PTMs specifically in the different etiologies 
linked to end-stage HF. Although these potential follow-up experiments are limited by 
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the unavailability of large amounts of control cardiac samples, and by the lack of 
specific antibodies targeting NaV1.5 N-terminal acetylation, and arginine methylation, 
our current results uncover novel NaV1.5 PTMs that can be explored as drivers or 
markers of end-stage HF.  
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